PL2419728T3 - Biomarker do monitorowania pacjentów - Google Patents

Biomarker do monitorowania pacjentów

Info

Publication number
PL2419728T3
PL2419728T3 PL10719285T PL10719285T PL2419728T3 PL 2419728 T3 PL2419728 T3 PL 2419728T3 PL 10719285 T PL10719285 T PL 10719285T PL 10719285 T PL10719285 T PL 10719285T PL 2419728 T3 PL2419728 T3 PL 2419728T3
Authority
PL
Poland
Prior art keywords
biomarker
monitoring patients
patients
monitoring
Prior art date
Application number
PL10719285T
Other languages
English (en)
Inventor
Bruce Acres
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PL2419728T3 publication Critical patent/PL2419728T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/00117Mucins, e.g. MUC-1
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL10719285T 2009-04-17 2010-04-12 Biomarker do monitorowania pacjentów PL2419728T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305328 2009-04-17
EP10719285.8A EP2419728B1 (en) 2009-04-17 2010-04-12 Biomarker for monitoring patients
PCT/EP2010/054743 WO2010119003A1 (en) 2009-04-17 2010-04-12 Biomarker for monitoring patients

Publications (1)

Publication Number Publication Date
PL2419728T3 true PL2419728T3 (pl) 2014-05-30

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10719285T PL2419728T3 (pl) 2009-04-17 2010-04-12 Biomarker do monitorowania pacjentów

Country Status (27)

Country Link
US (2) US20120058493A1 (pl)
EP (1) EP2419728B1 (pl)
JP (1) JP5661738B2 (pl)
KR (1) KR20120027146A (pl)
CN (1) CN102395883B (pl)
AU (1) AU2010237215B2 (pl)
BR (1) BRPI1010512A2 (pl)
CA (1) CA2759050A1 (pl)
CO (1) CO6440591A2 (pl)
CR (1) CR20110513A (pl)
CY (1) CY1114910T1 (pl)
DK (1) DK2419728T3 (pl)
ES (1) ES2445146T3 (pl)
HK (1) HK1163246A1 (pl)
HR (1) HRP20140262T1 (pl)
IL (1) IL214917A (pl)
MX (1) MX2011010920A (pl)
NZ (1) NZ594896A (pl)
PL (1) PL2419728T3 (pl)
PT (1) PT2419728E (pl)
RU (1) RU2555340C2 (pl)
SG (1) SG175060A1 (pl)
SI (1) SI2419728T1 (pl)
SM (1) SMT201400046B (pl)
TW (1) TWI426270B (pl)
WO (1) WO2010119003A1 (pl)
ZA (1) ZA201107545B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6375947B2 (ja) * 2012-05-11 2018-08-22 味の素株式会社 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
WO2019113449A1 (en) * 2017-12-08 2019-06-13 Stc.Unm In vivo imaging of tumor infiltration leukocytes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
EP0954593A1 (en) 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1998037095A2 (en) 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
DK1147181T3 (da) 1999-02-04 2004-09-20 Geron Corp Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1230378B1 (en) 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20040133243A1 (en) 2002-07-26 2004-07-08 Santamore William P. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
PT1896051E (pt) * 2005-06-28 2015-01-13 Oncothyreon Inc Método de tratamento de pacientes com uma vacina de glicoproteína mucinosa (muc-1)
CN101541342A (zh) * 2006-12-05 2009-09-23 特朗斯吉有限公司 产生提高的免疫应答的手段和方法
CN102046196B (zh) * 2008-05-29 2014-07-30 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法

Also Published As

Publication number Publication date
US20140141039A1 (en) 2014-05-22
TWI426270B (zh) 2014-02-11
MX2011010920A (es) 2011-11-04
SMT201400046B (it) 2014-05-07
EP2419728A1 (en) 2012-02-22
RU2011146419A (ru) 2013-05-27
HK1163246A1 (en) 2012-09-07
AU2010237215A1 (en) 2011-09-22
IL214917A0 (en) 2011-11-30
PT2419728E (pt) 2014-03-12
CA2759050A1 (en) 2010-10-21
SG175060A1 (en) 2011-11-28
CN102395883B (zh) 2015-12-02
AU2010237215B2 (en) 2014-05-01
CN102395883A (zh) 2012-03-28
EP2419728B1 (en) 2014-01-08
JP2012524248A (ja) 2012-10-11
IL214917A (en) 2016-03-31
CY1114910T1 (el) 2016-12-14
CR20110513A (es) 2012-01-06
KR20120027146A (ko) 2012-03-21
ZA201107545B (en) 2012-07-25
HRP20140262T1 (hr) 2014-04-25
RU2555340C2 (ru) 2015-07-10
ES2445146T3 (es) 2014-02-28
BRPI1010512A2 (pt) 2016-03-15
SI2419728T1 (sl) 2014-03-31
DK2419728T3 (da) 2014-02-03
NZ594896A (en) 2013-07-26
JP5661738B2 (ja) 2015-01-28
US20120058493A1 (en) 2012-03-08
WO2010119003A1 (en) 2010-10-21
CO6440591A2 (es) 2012-05-15
TW201040530A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
GB2511656B (en) Fracture monitoring
EP2485203A4 (en) DEVICE FOR MONITORING THE SURROUNDINGS OF A VEHICLE
EP2434759A4 (en) MONITOR
EP2485188A4 (en) SURVEILLANCE SYSTEM
GB201017389D0 (en) Condition monitoring system
HK1165206A1 (en) Biomarker for selecting patients and related methods
GB0921329D0 (en) Biomarker
GB0914915D0 (en) System monitoring
EP2416701A4 (en) SURVEILLANCE OF PERIPHERAL DECOUPLING
IL217447A (en) Bounce system
HK1163246A1 (en) Biomarker for monitoring patients
HK1161644A1 (en) Biomarker for monitoring patients
IL217333A0 (en) Biomarker
GB0913867D0 (en) Well monitoring system
GB0912175D0 (en) Biomarker
GB0909038D0 (en) Well monitoring
GB0919915D0 (en) Well monitoring
GB0900821D0 (en) Condition monitoring
GB0901450D0 (en) Exhaler device for monitoring disease
GB0913893D0 (en) Monitoring apparatus
GB0900872D0 (en) Contamination monitoring
GB0915278D0 (en) Biomarker
GB0913310D0 (en) Biomarker
GB0912153D0 (en) Biomarker
GB0921710D0 (en) Monitoring system